

Additional file I:

## PRISMA-P 2015 Checklist

This checklist has been adapted for use with systematic review protocol submissions to BioMed Central journals from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

An Editorial from the Editors-in-Chief of *Systematic Reviews* details why this checklist was adapted - Moher D, Stewart L & Shekelle P: Implementing PRISMA-P: recommendations for prospective authors. *Systematic Reviews* 2016 5:15

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
<b>ADMINISTRATIVE INFORMATION</b>					
<b>Title</b>					
Identification	1a	Identify the report as a protocol of a scoping review	X		1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such		X	
<b>Registration</b>	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	X		80-81
<b>Authors</b>					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	X		3-52
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	X		376-387, 400
<b>Amendments</b>	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments		X	
<b>Support</b>					
Sources	5a	Indicate sources of financial or other support for the review	X		389
Sponsor	5b	Provide name for the review funder and/or sponsor	X		389
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	X		407-408

**A scoping review protocol on *in vivo* human plastic exposure and health impacts**

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
<b>INTRODUCTION</b>					
<b>Rationale</b>	6	Describe the rationale for the review in the context of what is already known	X		120-142
<b>Objectives</b>	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	X		144-160
<b>METHODS</b>					
<b>Eligibility criteria</b>	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	X		159-224
<b>Information sources</b>	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	X		242, 255-258
<b>Search strategy</b>	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	X		241-262, Details will be included in the final scoping review paper
<b>STUDY RECORDS</b>					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	X		273-274
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	X		275-298
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	X		305-314
<b>Data items</b>	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	X		305-307
<b>Outcomes and prioritization</b>	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	X		197-218, 316-320
<b>Risk of bias in individual studies</b>	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis		X	318 (no risk of bias assessment, as this is a scoping review)

**A scoping review protocol on *in vivo* human plastic exposure and health impacts**

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
<b>DATA</b>					
<b>Synthesis</b>	15a	Describe criteria under which study data will be quantitatively synthesized		X	
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., $I^2$ , Kendall's tau)		X	
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)		X	
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned		X	
<b>Meta-bias(es)</b>	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)		X	
<b>Confidence in cumulative evidence</b>	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)		X	